Here's why the Amplia (ASX:ATX) share price is up 9% today

The Amplia Therapeutics Ltd (ASX: ATX) share price is running 9% higher today following progress on its AM945 inhibitor. Here's the details.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Amplia Therapeutics Ltd (ASX: ATX) share price is running higher today following the initiation of a multiple-dose study using AM945.

During late-morning trade, shares in the Australian pharmaceutical company are up 7% to 29 cents.

Amplia is an Australian pharmaceutical company. The company is focusing on the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. It's lead novel oral molecule, AMP945, is a "pure-play" inhibitor. This targets the formation of scar tissue (fibrosis) both in cancer and diseases such as idiopathic pulmonary fibrosis.

AMP945 is aimed at blocking FAK's activity which lessens scar tissue. Thus, AMP945 allows cancer treatments to be more effective without fibrosis.

What did Amplia announce?

The Amplia share price is on the move today. This comes after the report that it has progressed in the development of its novel inhibitor.

According to its release, Amplia advised that it has commenced a multiple ascending dose (MAD) study in its phase 1 clinical trial of AMP945. The decision to advance the FAK inhibitor was based on the positive results seen to date.

Amplia stated that during phase 1 trial, healthy volunteers undertook a single ascending dose (SAD) of AMP945. Patients were carefully monitored to gain a better understanding of the safety and tolerability parameters. As the initial study nears completion, it was revealed that no health issues were identified regarding the SAD administered to volunteers.

In light of the positive developments, Amplia decided to begin a MAD study involving 3 cohorts of subjects. The first lot of patients will be receiving their doses sometime this week. Different amounts will be administered to each group. The MAD study will run for a period of 7 days.

The data from both the SAD and MAD studies will help Amplia establish the desired dose of AMP945. This will be important for its future phase 2 clinical trial. Amplia is expecting that phase 2 will be commencing at the end of the 2021 calendar year.

Additionally, Amplia noted that it was also studying the impact of food on the absorption of AMP945. Amplia is currently analysing results after the separate trial concluded last month.

Words from the CEO

Amplia CEO, John Lambert, welcomed the company's progress, saying:

We are delighted that we have been able to advance AMP945 into our MAD study on the basis of the positive data seen so far in the SAD study. AMP945 is a very specific inhibitor of the FAK enzyme and has very little off-target activity. The excellent safety profile that we have seen in our SAD study to date is consistent with data from our preceding non-clinical studies.

We are very encouraged by the data that we have seen from the trial so far and look forward to reporting headline results from this Phase 1 clinical trial in Q2 2021.

About the Amplia share price

In the past 12 months, the Amplia shares have risen close to 200% reflecting positive investor sentiment. During March, its shares dipped to a 52-week low of 4.5 cents before storming higher to 37 cents in October.

Swapping hands for 29 cents today, the company's shares are only 25% away from its multi-year high.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

a couple look dumbfounded with exaggerated looks of surpirse on their faces as te mman holds a phone in his hand.
Share Market News

Top 5 investment themes exciting ASX shares investors in FY25

There's some old themes and some new ones...

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Share Gainers

Here are the top 10 ASX 200 shares today

It was certainly a day to remember for ASX investors this Friday...

Read more »

Hands reaching high for a trophy with a sunset in the background.
Investing Strategies

3 reasons I'm still buying ASX stocks in July despite record prices

There are many reasons not to invest. A new high is not one of them.

Read more »

Three girls compete in a race, running fast around an athletic track.
Share Gainers

Do you own the 3 best performing ASX 200 shares of FY 2025?

The top three ASX 200 shares have already gained 13% to more than 20% in FY 2025!

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
Share Market News

Buying shares and 5 other ways investors intend to spend tax cuts: report

Here's what Aussie investors plan to do with their tax-cut savings.

Read more »

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Materials Shares

Down 79% in FY 2024, can the Sayona Mining share price rebound in FY 2025?

Sayona Mining shares got smashed in FY 2024 with investors now looking ahead to FY 2025.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Immutep, Kingsgate, Netwealth, and Ora Banda shares are storming higher

These shares are ending the week with a bang. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why GR Engineering, Infratil, Paladin Energy, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »